Navigation Links
Potential anti-TNF response biomarker identified
Date:6/12/2014

DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies.1 These data, presented today at the European League Against Rheumatism Annual Congress (EULAR 2014), bring clinicians a step closer to being able to personalise a patient's treatment pathway.

Anti-TNF therapies have proved a huge advance for the treatment of rheumatoid arthritis and have transformed the treatment of inflammatory arthritis for millions of people around the world. However, only 20-40% of patients achieve a good response according to EULAR criteria.2

"It can take several years to identify the most effective treatment for an RA patient. This is not only costly in terms of the financial burden, but also in terms of patient outcomes and the irreversible joint damage that is being done," said Amy Webster, University of Manchester, United Kingdom. "Because of this, the identification of biomarkers that can predict a patient's response to a treatment is an important area of research which will allow the most effective treatment for each patient to be identified early in the course of the disease."

She continued, "Based on recent studies showing a role for epigenetics in RA and other autoimmune disorders, we hypothesised that epigenetic changes, such as DNA methylation, may provide potential biomarkers of response to anti-TNFs."

RA is a chronic systemic disease that affects the joints, connective tissues, muscle, tendons, and fibrous tissue. A disabling condition that often causes pain and deformity, symptoms of RA tend to appear between the ages of 20 and 40. The prevalence of RA globally varies between 0.3% and 1% and is more common in women and in developed countries. Within 10 years of onset, at least 50% of patients in developed countries are unable to maintain a full-time job.3 1In this study, patients were selected from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) longitudinal cohort based on having an extreme response phenotype after three months of treatment with etanercept or adalimumab. Of the patients in the study, 36 patients were good responders to etanercept and 45 to adalimumab as defined by having an endpoint of DAS28<2.6. Poor responders to etanercept (35) and adalimumab (27) were defined by having an improvement of <0.6 or between 0.6-1.2 with an endpoint DAS28 of >5.1.

DNA from each patient was sampled before therapy was initiated. Following bisulfite conversion of the DNA, an epigenome-wide association study was conducted using the HumanMethylation450 BeadChip (Illumina) to determine unmethylated versus methylated cytosines within the DNA. The results from each drug were analysed separately and together using the minfi package in R and probes with a detection-p value > 0.01 were removed. Differentially methylated positions between responders and non-responders were identified using the F-test following quantile normalisation.

In the etanercept study, four CpG* sites showed differential DNA methylation that passed a false discovery rate of 0.05, while in the adalimumab study less significant results were observed. The most differentially methylated position in etanercept patients mapped to the LRPAP1 gene (p=1.46x10-8). This gene encodes a chaperone of low density lipoprotein receptor-related protein 1 (LRP1) which is known to influence TGF-β activity. Technical validation of methylation at this site by pyrosequencing showed very good correlation (Spearmans r=0.8). In the adalimumab patients, the most differentially methylated position maps to the PDZD8 gene. Joint analysis of the two drugs together identified a differentially methylated region overlapping the CRYZ and TYW3 genes, which have previously been associated with inflammation and Type 2 diabetes.4


'/>"/>
Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-078-801-73209
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
2. Molecule linked to aggressive pancreatic cancer offers potential clinical advances
3. Cancers potential on-off switch
4. Study points to potential revision of treatment guidelines for bleeding ulcers
5. How bacteria exploit proteins to trigger potentially lethal infections
6. Microfluidic technology reveals potential biomarker for early pancreatic cancer
7. Researchers identify potential new strategy to treat ovarian cancer
8. Revolutionary metamaterial has potential to reshape neurosurgery
9. Scientists identify cancer specific cell for potential treatment of gastric cancer
10. CT measures potentially dangerous arterial plaque in diabetic patients
11. Live cell imaging reveals distinct alterations of subcellular glutathione potentials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of American respondents ... family members or friends have also commented about their poor hearing. However, only ... aids. One reason, suggested by 89 percent of American respondents, is that they ...
(Date:2/22/2017)... North Carolina (PRWEB) , ... February 22, 2017 , ... ... of cats and 54% of dogs, according to the Association for Pet Obesity Prevention ... disagreed on key pet food issues such as the benefits of corn and grains, ...
(Date:2/22/2017)... SC (PRWEB) , ... February 22, 2017 , ... ... of several sponsors of the Medical University of South Carolina (MUSC) Center on Aging’s ... Mount Pleasant, SC. “MUSC’s Center on Aging is a tremendous resource in our community. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to ... Multi-Cook Oven offers up to four ovens in one. Control temperature, fan speed ... unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has a passion for using ... family to know all about it for optimal health. Wanting to share her knowledge ... Detox, Digestive and Wellness Solutions ” (published by Balboa Press AU). , This ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... full fiscal year ended December 31, 2016. ... This news release ... statements and management discussion and analysis for the years ended ... SEDAR and are available at www.sedar.com and on ...
(Date:2/22/2017)... Feb. 22, 2017 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... its Fourth Quarter 2016 investor conference call and webcast at ... The call will cover an update on Merrimack,s recent ... full year 2016 financial results. A press release detailing the ... the morning of Wednesday, March 1. Investors and the general ...
(Date:2/22/2017)... -- Summary Provides understanding and access to ... entered into by the worlds leading healthcare companies. ... The Global Non-Small Cell Lung Cancer Partnering Terms and ... partnering deals and agreements entered into by the world,s ... deals - Top deals by value - ...
Breaking Medicine Technology: